Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer.
Kobayashi Y, Kashima H, Rahmanto YS, Banno K, Yu Y, Matoba Y, Watanabe K, Iijima M, Takeda T, Kunitomi H, Iida M, Adachi M, Nakamura K, Tsuji K, Masuda K, Nomura H, Tominaga E, Aoki D.
Kobayashi Y, et al. Among authors: watanabe k.
Oncotarget. 2017 Aug 7;8(42):72147-72156. doi: 10.18632/oncotarget.20046. eCollection 2017 Sep 22.
Oncotarget. 2017.
PMID: 29069775
Free PMC article.